Ground-breaking blood test could reduce lung cancer deaths
08 Sep 2019
"A ground-breaking blood test could cut the number of people who die from lung cancer each year.
Lung cancer is the third most common cancer but it has a very high mortality rate. Less than 9% of patients survive more than five year after diagnosis - often because it is spotted too late.
A trial of 12,209 high-risk patients in Scotland found that those who took the blood test were diagnosed at an earlier stage than those who received standard care.
Oncimmune Holdings, the global company that designed the test, said it works by detecting autoantibodies made by the body's immune system as a natural defence against cancer cells."
These landmark findings are likely to have globally significant implications for the early detection of lung cancer by showing how a simple blood test, followed by CT scans, is able to increase the number of patients diagnosed at an earlier stage of the disease, when surgery is still possible and prospects for survival much higher.
Professor Frank Sullivan, Professor of Primary Care Medicine at the University of St Andrews and Chief Investigator for the ECLS trial.